Get the Stockscreener App
1.62
0.62%
0.01
After Hours:
1.62
Clearmind Medicine Inc stock is traded at $1.62, with a volume of 39,866.
It is up +0.62% in the last 24 hours and down -31.93% over the past month.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
See More
Previous Close:
$1.61
Open:
$1.61
24h Volume:
39,866
Relative Volume:
0.02
Market Cap:
$2.41M
Revenue:
-
Net Income/Loss:
$-7.90M
P/E Ratio:
-0.00871
EPS:
-185.9263
Net Cash Flow:
$-6.29M
1W Performance:
-13.37%
1M Performance:
-31.93%
6M Performance:
-93.96%
1Y Performance:
-99.61%
1-Day Range:
$1.5801
$1.63
1-Week Range:
$1.5801
$1.7929
52-Week Range:
$1.5801
$524.00
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
1.62 | 2.39M | 0 | -7.90M | -6.29M | -185.93 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Clearmind Medicine Inc Stock (CMND) Latest News
Clearmind Medicine Inc (CMND) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Clearmind Medicine Inc. Revenue Breakdown – FWB:CWY0 - TradingView
Clearmind Medicine Inc (CMND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Clearmind Medicine Inc (CMND) Valuation: PE, PB & Fair Value Analysis - TradingKey
Clearmind Medicine Inc (CMND) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Clearmind Medicine Inc (CMND) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CMND|Clearmind Medicine Inc|Price:1.628|Chg%:+0.018 - TradingKey
CMND|Clearmind Medicine Inc|Price:1.615|Chg%:-0.045 - TradingKey
Clearmind Medicine Inc (CMND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Clearmind Medicine Inc (CMND) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Clearmind Medicine (CMND) Stock Forecast & Analyst Ratings - Moomoo
Clearmind Medicine Inc. (CMND) Stock Price, News, Quote & History - Yahoo! Finance Canada
Clearmind files Hong Kong patent for PTSD treatment compounds - Investing.com
Clearmind Medicine Files Hong Kong Patent Application for PTSD-Targeting Compounds - Quiver Quantitative
Clearmind's PTSD Filing Targets Market Projected at $30.2B - Stock Titan
Clearmind submits addiction treatment proposal to U.S. HHS By Investing.com - Investing.com Nigeria
Clearmind Medicine Expends Global IP Portfolio With Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‐Billion‐Dollar PTSD Therapeutics Market - Moomoo
Clearmind Medicine comments on federal psychedelic guidance By Investing.com - Investing.com South Africa
Clearmind Medicine comments on federal psychedelic guidance - Investing.com UK
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction - The Manila Times
Clearmind reports mucoadhesion results for intranasal MEAI formulation By Investing.com - Investing.com Nigeria
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI - The Manila Times
Clearmind Medicine Reports Improved Mucoadhesion for Intranasal MEAI Formulation in Ex Vivo Study - Quiver Quantitative
Clearmind's MEAI formulation stayed longer on nasal tissue in testing - Stock Titan
Clearmind Medicine Inc. sees price surge amid market decline - Intellectia AI
Clearmind shares CMND-100 trial insights - grafa.com
Clearmind reports positive early data from alcohol disorder trial - Investing.com UK
Clearmind reports positive early data from alcohol disorder trial By Investing.com - Investing.com Canada
Clearmind's trial shows promising safety and po... - Pluang
Clearmind Medicine Reports Positive Early Experience in Phase I/IIa Trial of Non-Hallucinogenic MEAI for Alcohol Use Disorder - Quiver Quantitative
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial - Yahoo Finance Singapore
Clearmind Medicine (CMND) Slides 1.93% as Shares Approach Critical $1.93 SupportVOLD Alert - dars.gov.et
Clearmind Medicine (Nasdaq: CMND) details neuroplastogen-based response to U.S. addiction RFI - Stock Titan
Clearmind Medicine Submits Formal Response To HHS RFI Highlighting MEAI-Based Candidate CMND-100 For Alcohol Use Disorder And Binge Behaviors - marketscreener.com
Clearmind submits addiction treatment proposal to U.S. HHS - Investing.com India
Clearmind submits MEAI addiction treatment prop... - Pluang
Clearmind Medicine Submits Response to HHS RFI Highlighting MEAI-Based CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative - The Manila Times
Clearmind Medicine (CMND) reports successful intranasal MEAI feasibility study - Stock Titan
Clearmind reports MEAI intranasal study progress - grafa.com
Clearmind Medicine : Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration for MEAI - marketscreener.com
CMND Stock Slides As Traders Gauge Cash Runway And Volatility - StocksToTrade
Clearmind advances intranasal delivery studies for addiction drug By Investing.com - Investing.com Nigeria
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI - The Manila Times
Clearmind Medicine Reports Successful Formulation Feasibility for Intranasal MEAI Development Program for Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Company Profile & Introduction - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Clearmind Medicine receives U.S. patent for binge behavior treatment - Investing.com UK
Clearmind Medicine receives U.S. patent for binge behavior treatment By Investing.com - Investing.com Australia
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength - The Manila Times
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):